Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases

References

• Yao H, Rahman I. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol Appl Pharmacol. 2011;254:72–85. doi:10.1016/j.taap.2009.10.02221296096
   PubMed Web of Science ®Google Scholar
• Thorley AJ, Tetley TD. Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2007;2:409–428.18268916
   PubMedGoogle Scholar
• van Eeden SF, Sin DD. Oxidative stress in chronic obstructive pulmonary disease: a lung and systemic process. Can Respir J. 2013;20:27–29. doi:10.1155/2013/50913023457671
   PubMed Web of Science ®Google Scholar
• Silva-Palacios A, Ostolga-Chavarría M, Sánchez-Garibay C, et al. Sulforaphane protects from myocardial ischemia-reperfusion damage through the balanced activation of Nrf2/AhR. Free Radic Biol Med. 2019;143:331–340. doi:10.1016/j.freeradbiomed.2019.08.01231422078
   PubMed Web of Science ®Google Scholar
• Lin X, Bai D, Wei Z, et al. Curcumin attenuates oxidative stress in RAW264.7 cells by increasing the activity of antioxidant enzymes and activating the Nrf2-Keap1 pathway. PLoS One. 2019;14:e0216711. doi:10.1371/journal.pone.021671131112588
   PubMed Web of Science ®Google Scholar
• Kumar H, Kim IS, More SV, Kim BW, Choi DK. Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases. Nat Prod Rep. 2014;31:109–139.24292194
   PubMed Web of Science ®Google Scholar
• Rahman I, Macnee W. Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol. 2012;12:256–265.
   Google Scholar
• Rahman I. Antioxidant therapies in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:15–29. doi:10.2147/copd.2006.1.1.1518046899
   PubMedGoogle Scholar
• Sadowska AM, Verbraecken J, Darquennes K, De Backer WA. Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:425–434. doi:10.2147/copd.2006.1.4.42518044098
   PubMedGoogle Scholar
• Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N -acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther. 2008;8:1955–1962. doi:10.1517/1472822080251790118990082
   PubMed Web of Science ®Google Scholar
• Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol. 1989;36:127–131. doi:10.1007/BF006091832721538
   PubMed Web of Science ®Google Scholar
• Rubio ML, Martin-Mosquero MC, Ortega M, Peces-Barba G, González-Mangado N. Oral N-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats. Chest. 2004;125:1500–1506. doi:10.1378/chest.125.4.150015078764
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res. 2017;18:26. doi:10.1186/s12931-016-0500-y28118826
   PubMed Web of Science ®Google Scholar
• Adler KB, Hendley DD, Davis GS. Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways. Am J Pathol. 1986;125:501–514.3099581
   PubMed Web of Science ®Google Scholar
• Besaratinia A, Besarati Nia A, Maas LM, et al. Applicability of induced sputum for molecular dosimetry of exposure to inhalatory carcinogens: 32P-postlabeling of lipophilic DNA adducts in smokers and nonsmokers. Cancer Epidemiol Biomarkers Prev. 2000;9:367–372.10794480
   PubMed Web of Science ®Google Scholar
• De Benedetto F, Aceto A, Dragani B, et al. Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther. 2005;18:41–47. doi:10.1016/j.pupt.2004.09.03015607126
   PubMed Web of Science ®Google Scholar
• Aylward M, Maddock J, Dewland P. Clinical evaluation of acetylcysteine in the treatment of patients with chronic obstructive bronchitis: a balanced double-blind trial with placebo control. Eur J Respir Dis Suppl. 1980;111:81–89.7011835
   PubMedGoogle Scholar
• Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000;16:253–262. doi:10.1034/j.1399-3003.2000.16b12.x10968500
   PubMed Web of Science ®Google Scholar
• Lee KS, Kim SR, Park HS, et al. A novel thiol compound, N-acetylcysteine amide, attenuates allergic airway disease by regulating activation of NF-κB and hypoxia-inducible factor-1α. Exp Mol Med. 2007;39:756–768. doi:10.1038/emm.2007.8218160846
   PubMed Web of Science ®Google Scholar
• Koechlin C, Couillard A, Cristol JP, et al. Does systemic inflammation trigger local exercise-induced oxidative stress in COPD? Eur Respir J. 2004;23:538–544. doi:10.1183/09031936.04.0006900415083751
   PubMed Web of Science ®Google Scholar
• Dueholm M, Nielsen C, Thorshauge H, et al. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir Med. 1992;86:89–92. doi:10.1016/S0954-6111(06)80220-91615189
   PubMed Web of Science ®Google Scholar
• Antonicelli F, Parmentier M, Drost EM, et al. Nacystelyn inhibits oxidant-mediated interleukin-8 expression and NF-kappaB nuclear binding in alveolar epithelial cells. Free Radic Biol Med. 2002;32:492–502. doi:10.1016/S0891-5849(01)00820-611958950
   PubMed Web of Science ®Google Scholar
• Antonicelli F, Brown D, Parmentier M, et al. Regulation of LPS-mediated inflammation in vivo and in vitro by the thiol antioxidant Nacystelyn. Am J Physiol Cell Mol Physiol. 2004;286:L1319–L1327. doi:10.1152/ajplung.00329.2003
   PubMed Web of Science ®Google Scholar
• Gillissen A, Jaworska M, Orth M, et al. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir Med. 1997;91:159–168. doi:10.1016/S0954-6111(97)90052-49135855
   PubMed Web of Science ®Google Scholar
• Elborn JS, Bell SC, Madge SL, et al. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. Eur Respir J. 2016;47:420–428. doi:10.1183/13993003.00592-201526453627
   PubMed Web of Science ®Google Scholar
• Ekberg-Jansson A, Larson M, MacNee W, et al. N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. Eur Respir J. 1999;13:829–834. doi:10.1034/j.1399-3003.1999.13d22.x10362048
   PubMed Web of Science ®Google Scholar
• Macciò A, Madeddu C, Panzone F, Mantovani G. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin Pharmacother. 2009;10:693–703. doi:10.1517/1465656090275834319239402
   PubMed Web of Science ®Google Scholar
• Braga PC, Allegra L, Rampoldi C, Ornaghi A, Beghi G. Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. Respiration. 1990;57:353–358. doi:10.1159/0001958712099568
   PubMed Web of Science ®Google Scholar
• Yasuo M, Fujimoto K, Imamura H, et al. l-Carbocisteine reduces neutrophil elastase-induced mucin production. Respir Physiol Neurobiol. 2009;167:214–216. doi:10.1016/j.resp.2009.04.01619394453
   PubMed Web of Science ®Google Scholar
• Yoshida M, Nakayama K, Yasuda H, et al. Carbocisteine inhibits oxidant-induced apoptosis in cultured human airway epithelial cells. Respirology. 2009;14:1027–1034. doi:10.1111/j.1440-1843.2009.01594.x19664007
   PubMed Web of Science ®Google Scholar
• Pace E, Ferraro M, Siena L, et al. Carbocysteine regulates innate immune responses and senescence processes in cigarette smoke stimulated bronchial epithelial cells. Toxicol Lett. 2013;223:198–204. doi:10.1016/j.toxlet.2013.09.01324076166
   PubMed Web of Science ®Google Scholar
• Wang W, Zheng J-P, Zhu S-X, et al. Carbocisteine attenuates hydrogen peroxide-induced inflammatory injury in A549 cells via NF-κB and ERK1/2 MAPK pathways. Int Immunopharmacol. 2015;24:306–313. doi:10.1016/j.intimp.2014.12.01825533503
   PubMed Web of Science ®Google Scholar
• Hooper C, Calvert J. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Int J COPD. 2008;3:659–669. doi:10.2147/COPD.S3735
   Google Scholar
• Zheng CH, Ahmed K, Rikitomi N, Martinez G, Nagatake T. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol. 1999;43:107–113. doi:10.1111/j.1348-0421.1999.tb02381.x10229264
   PubMed Web of Science ®Google Scholar
• Cakan G, Turkoz M, Turan T, Ahmed K, Nagatake T. S-carboxymethylcysteine inhibits the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells. Microb Pathog. 2003;34:261–265. doi:10.1016/S0882-4010(03)00048-212782478
   PubMed Web of Science ®Google Scholar
• Moretti M, Fagnani S. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2319–2325. doi:10.2147/COPD.S8709126604731
   PubMed Web of Science ®Google Scholar
• Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res. 2004;30:143–152.15553660
   PubMedGoogle Scholar
• Moretti M. Erdosteine: its relevance in COPD treatment. Expert Opin Drug Metab Toxicol. 2009;5:333–343. doi:10.1517/17425250902814790
   Google Scholar
• Dal Negro, R.W., Wedzicha, J.A., Iversen, M., Fontana, G., Page, C., Cicero, A.F., Pozzi, E. and Calverley, P.M., 2017. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 50:1700711 .
   Google Scholar
• Cazzola M, Floriani I, Page CP. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm Pharmacol Ther. 2010;23:135–144. doi:10.1016/j.pupt.2009.10.00219854285
   PubMed Web of Science ®Google Scholar
• Negro RWD. Erdosteine: antitussive and anti-inflammatory effects. Lung. 2008;186:70–73. doi:10.1007/s00408-007-9065-3
   Web of Science ®Google Scholar
• Dal Negro RW, Visconti M, Tognella S, Micheletto C. Erdosteine affects eicosanoid production in COPD. Int J Clin Pharmacol Ther. 2011;49:41–45. doi:10.5414/CPP4904121176724
   PubMed Web of Science ®Google Scholar
• Komatsu H, Yamaguchi S, Komorita N, et al. Inhibition of endotoxin- and antigen-induced airway inflammation by fudosteine, a mucoactive agent. Pulm Pharmacol Ther. 2005;18:121–127. doi:10.1016/j.pupt.2004.11.00215649854
   PubMed Web of Science ®Google Scholar
• Rhee CK, Kang CM, You MB, et al. Effect of fudosteine on mucin production. Eur Respir J. 2008;32:1195–1202. doi:10.1183/09031936.0001850818579549
   PubMed Web of Science ®Google Scholar
• Osoata GO, Hanazawa T, Brindicci C, et al. Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest. 2009;135:1513–1520. doi:10.1378/chest.08-210519188555
   PubMed Web of Science ®Google Scholar
• Hodge S, Matthews G, Mukaro V, et al. Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine. Am J Respir Cell Mol Biol. 2011;44:673–681. doi:10.1165/rcmb.2009-0459OC20595463
   PubMed Web of Science ®Google Scholar
• Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 2007;47:89–116. doi:10.1146/annurev.pharmtox.46.120604.14104616968214
   PubMed Web of Science ®Google Scholar
• Sykiotis GP, Bohmann D. Stress-activated cap’n’collar transcription factors in aging and human disease. Sci Signal. 2010;3:re3. doi:10.1126/scisignal.3112re320215646
   PubMed Web of Science ®Google Scholar
• Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal. 2010;13:1665–1678. doi:10.1089/ars.2010.322220446768
   PubMed Web of Science ®Google Scholar
• Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP-Y. DJ-1, a cancer- and Parkinson’s disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci. 2006;103:15091–15096. doi:10.1073/pnas.060726010317015834
   PubMed Web of Science ®Google Scholar
• Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med. 2009;47:1304–1309. doi:10.1016/j.freeradbiomed.2009.07.03519666107
   PubMed Web of Science ®Google Scholar
• Plafker KS, Nguyen L, Barneche M, et al. The ubiquitin-conjugating enzyme UbcM2 can regulate the stability and activity of the antioxidant transcription factor Nrf2. J Biol Chem. 2010;285:23064–23074. doi:10.1074/jbc.M110.12191320484052
   PubMed Web of Science ®Google Scholar
• Keum Y-S, Yu S, Chang PP-J, et al. Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element–mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res. 2006;66:8804–8813. doi:10.1158/0008-5472.CAN-05-351316951197
   PubMed Web of Science ®Google Scholar
• Yoon H-Y, Kang N-I, Lee H-K, et al. Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol. 2008;75:2214–2223. doi:10.1016/j.bcp.2008.02.02918407246
   PubMed Web of Science ®Google Scholar
• Suzuki M, Betsuyaku T, Ito Y, et al. Curcumin attenuates elastase- and cigarette smoke-induced pulmonary emphysema in mice. Am J Physiol Cell Mol Physiol. 2009;296:L614–L623. doi:10.1152/ajplung.90443.2008
   PubMed Web of Science ®Google Scholar
• Chen C-Y, Jang J-H, Li M-H, Surh Y-J. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun. 2005;331:993–1000. doi:10.1016/j.bbrc.2005.03.23715882976
   PubMed Web of Science ®Google Scholar
• Kode A, Rajendrasozhan S, Caito S, et al. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Cell Mol Physiol. 2008;294:L478–L488. doi:10.1152/ajplung.00361.2007
   PubMed Web of Science ®Google Scholar
• Andreadi CK, Howells LM, Atherfold PA, Manson MM. Involvement of Nrf2, p38, B-raf and NF- B, but not PI3K, in induction of hemeoxygenase (HO-1) by dietary polyphenols. Mol Pharmacol. 2005;69:1033–1040. doi:10.1124/mol.105.01837416354769
   PubMed Web of Science ®Google Scholar
• Shah ZA, Li R-C, Ahmad AS, et al. The flavanol (−)-Epicatechin prevents stroke damage through the Nrf2/HO1 pathway. J Cereb Blood Flow Metab. 2010;30:1951–1961. doi:10.1038/jcbfm.2010.5320442725
   PubMed Web of Science ®Google Scholar
• Sussan TE, Rangasamy T, Blake DJ, et al. Targeting Nrf2 with the triterpenoid CDDO- imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci. 2009;106:250–255. doi:10.1073/pnas.080433310619104057
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Li J, Meyer CJ, et al. Dihydro-CDDO-trifluoroethyl amide (dh404), a Novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes. PLoS One. 2009;4:e8391. doi:10.1371/journal.pone.000839120027226
   PubMed Web of Science ®Google Scholar
• Hsu C-L, Wu Y-L, Tang G-J, Lee T-S, Kou YR. Ginkgo biloba extract confers protection from cigarette smoke extract-induced apoptosis in human lung endothelial cells: role of heme oxygenase-1. Pulm Pharmacol Ther. 2009;22:286–296. doi:10.1016/j.pupt.2009.02.00319254777
   PubMed Web of Science ®Google Scholar
• Yao P, Nussler A, Liu L, et al. Quercetin protects human hepatocytes from ethanol-derived oxidative stress by inducing heme oxygenase-1 via the MAPK/Nrf2 pathways. J Hepatol. 2007;47:253–261. doi:10.1016/j.jhep.2007.02.00817433488
   PubMed Web of Science ®Google Scholar
• Rushworth SA, Ogborne RM, Charalambos CA, O’Connell MA. Role of protein kinase C δ in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. Biochem Biophys Res Commun. 2006;341:1007–1016. doi:10.1016/j.bbrc.2006.01.06516460683
   PubMed Web of Science ®Google Scholar
• Muscoli C, Sacco I, Alecce W, et al. The protective effect of superoxide dismutase mimetic M40401 on balloon injury-related neointima formation: role of the lectin-like oxidized low-density lipoprotein receptor-1. J Pharmacol Exp Ther. 2004;311:44–50. doi:10.1124/jpet.104.06820515220383
   PubMed Web of Science ®Google Scholar
• Tuder RM, Zhen L, Cho CY, et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol biol. 2003;29:88–97. doi:10.1165/rcmb.2002-0228OC12600822
   PubMed Web of Science ®Google Scholar
• Chang L-Y, Crapo JD. Inhibition of airway inflammation and hyperreactivity by an antioxidant mimetic. Free Radic Biol Med. 2002;33:379–386. doi:10.1016/S0891-5849(02)00919-X12126760
   PubMed Web of Science ®Google Scholar
• Smith KR, Uyeminami DL, Kodavanti UP, et al. Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic Biol Med. 2002;33:1106–1114. doi:10.1016/S0891-5849(02)01003-112374622
   PubMed Web of Science ®Google Scholar
• Sharpe MA, Ollosson R, Stewart VC, Clark JB. Oxidation of nitric oxide by oxomanganese-salen complexes: a new mechanism for cellular protection by superoxide dismutase/catalase mimetics. Biochem J. 2002;366:97–107. doi:10.1042/bj2002015411994046
   PubMed Web of Science ®Google Scholar
• Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med. 2003;167:1600–1619. doi:10.1164/rccm.200212-1479SO12796054
   PubMed Web of Science ®Google Scholar
• Yao H, Arunachalam G, Hwang J-W, et al. Extracellular superoxide dismutase protects against pulmonary emphysema by attenuating oxidative fragmentation of ECM. Proc Natl Acad Sci. 2010;107:15571–15576. doi:10.1073/pnas.100762510720713693
   PubMed Web of Science ®Google Scholar
• Tollefson AK, Oberley-Deegan RE, Butterfield KT, et al. Endogenous enzymes (NOX and ECSOD) regulate smoke-induced oxidative stress. Free Radic Biol Med. 2010;49:1937–1946. doi:10.1016/j.freeradbiomed.2010.09.02220887783
   PubMed Web of Science ®Google Scholar
• József L, Filep JG. Selenium-containing compounds attenuate peroxynitrite-mediated NF-kappaB and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes. Free Radic Biol Med. 2003;35:1018–1027. doi:10.1016/S0891-5849(03)00439-814572605
   PubMed Web of Science ®Google Scholar
• Zhang M, Nomura A, Uchida Y, et al. Ebselen suppresses late airway responses and airway inflammation in guinea pigs. Free Radic Biol Med. 2002;32:454–464. doi:10.1016/S0891-5849(01)00825-511864785
   PubMed Web of Science ®Google Scholar
• Haddad E-B, McCluskie K, Birrell MA, et al. Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation. J Immunol. 2002;169:974–982. doi:10.4049/jimmunol.169.2.97412097404
   PubMed Web of Science ®Google Scholar
• Chabrier PE, Auguet M, Spinnewyn B, et al. BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy. Proc Natl Acad Sci U S A. 1999;96:10824–10829. doi:10.1073/pnas.96.19.1082410485910
   PubMed Web of Science ®Google Scholar
• Yhee JY, Im J, Nho RS. Advanced therapeutic strategies for chronic lung disease using nanoparticle-based drug delivery. J Clin Med. 2016;5:82. doi:10.3390/jcm5090082
   PubMed Web of Science ®Google Scholar
• Jiang J, Oberdörster G, Biswas P. Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies. Journal of Nanoparticle Research. 2009;11(1):77–89. doi:10.1007/s11051-008-9446-4
   Web of Science ®Google Scholar
• Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62:1052–1063. doi:10.1016/j.addr.2010.08.00420709124
   PubMed Web of Science ®Google Scholar
• van Rijt SH, Bein T, Meiners S. Medical nanoparticles for next generation drug delivery to the lungs. Eur Respir J. 2014;44:765–774. doi:10.1183/09031936.0021281324791828
   PubMed Web of Science ®Google Scholar
• Suk JS, Boylan NJ, Trehan K, et al. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol Ther. 2011;19:1981–1989. doi:10.1038/mt.2011.16021829177
   PubMed Web of Science ®Google Scholar
• Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv. 2008;5:629–639. doi:10.1517/17425247.5.6.62918532919
   PubMed Web of Science ®Google Scholar
• Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev. 2009;61:115–127. doi:10.1016/j.addr.2008.09.01119146894
   PubMed Web of Science ®Google Scholar
• Lai SK, Wang -Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61:158–171. doi:10.1016/j.addr.2008.11.00219133304
   PubMed Web of Science ®Google Scholar
• Geiser M, Quaile O, Wenk A, et al. Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease. Part Fibre Toxicol. 2013;10:19. doi:10.1186/1743-8977-10-1923680060
   PubMed Web of Science ®Google Scholar
• Geiser M, Stoeger T, Casaulta M, Chen S, Semmler-Behnke M, Bolle I, Takenaka S, Kreyling WG, Schulz H. Biokinetics of nanoparticles and susceptibility to particulate exposure in a murine model of cystic fibrosis. Particle and fibre toxicology. 2014 Dec;11(1):19.
   Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941–951. doi:10.1038/nbt.333026348965
   PubMed Web of Science ®Google Scholar
• Garbuzenko O, Mainelis G, Taratula O, Minko T. Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol Med. 2014;11:4424738038
   PubMedGoogle Scholar
• Geng Y, Dalhaimer P, Cai S, et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol. 2007;2:249–255. doi:10.1038/nnano.2007.7018654271
   PubMed Web of Science ®Google Scholar
• Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci. 2006;103:4930–4934. doi:10.1073/pnas.060099710316549762
   PubMed Web of Science ®Google Scholar
• Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res. 2009;26:244–249. doi:10.1007/s11095-008-9626-z18548338
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505–515. doi:10.1021/mp800051m18672949
   PubMed Web of Science ®Google Scholar
• Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano–bio interface. Nat Mater. 2009;8:543–557. doi:10.1038/nmat244219525947
   PubMed Web of Science ®Google Scholar
• Schütz CA, Juillerat-Jeanneret L, Mueller H, et al. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine. 2013;8:449–467. doi:10.2217/nnm.13.823477336
   PubMed Web of Science ®Google Scholar
• Oh YJ, Lee J, Seo JY, et al. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J Control Release. 2011;150:56–62. doi:10.1016/j.jconrel.2010.11.00121070826
   PubMed Web of Science ®Google Scholar
• Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target. 2011;19:900–914. doi:10.3109/1061186X.2011.62240421981718
   PubMed Web of Science ®Google Scholar
• Trapani. A, Gioia S, Castellani S, et al. Nanocarriers for respiratory diseases treatment: recent advances and current challenges. Curr Top Med Chem. 2014;14:1133–1147. doi:10.2174/156802661466614032922581724678708
   PubMed Web of Science ®Google Scholar
• da Silva AL, Cruz FF, Rocco PRM, Morales MM. New perspectives in nanotherapeutics for chronic respiratory diseases. Biophys Rev. 2017;9:793–803. doi:10.1007/s12551-017-0319-x28914424
   PubMedGoogle Scholar
• Gorain B, Choudhury H, Pandey M, et al. Dendrimer-based nanocarriers in lung Cancer therapy. In Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer. Academic Press; 2019:161–192.
   Google Scholar
• Zahoor A, Sharma S, Khuller GK, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents. 2005;26:298–303. doi:10.1016/j.ijantimicag.2005.07.01216154726
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83:761–769. doi:10.1038/sj.clpt.610040017957183
   PubMed Web of Science ®Google Scholar
• Yoo J-W, Doshi N, Mitragotri S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv Drug Deliv Rev. 2011;63:1247–1256. doi:10.1016/j.addr.2011.05.00421605607
   PubMed Web of Science ®Google Scholar
• Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4:219–233. doi:10.1002/wnan.115722231928
   PubMed Web of Science ®Google Scholar
• Doh K-O, Yeo Y. Application of polysaccharides for surface modification of nanomedicines. Ther Deliv. 2012;3:1447–1456. doi:10.4155/tde.12.10523323561
   PubMedGoogle Scholar
• Monopoli MP, Åberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012;7:779–786. doi:10.1038/nnano.2012.20723212421
   PubMed Web of Science ®Google Scholar
• Ruge CA, Schaefer UF, Herrmann J, et al. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PLoS One. 2012;7:e40775. doi:10.1371/journal.pone.004077522802970
   PubMed Web of Science ®Google Scholar
• Kumar P, Bohidar HB. Interaction of soot derived multi-carbon nanoparticles with lung surfactants and their possible internalization inside alveolar cavity. Indian J Exp Biol. 2010;48:1037–1042.21299046
   PubMed Web of Science ®Google Scholar
• Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156:1363–1380. doi:10.1016/S0002-9440(10)65006-710751361
   PubMed Web of Science ®Google Scholar
• Mehra NK, Mishra V, Jain NK. Receptor-based targeting of therapeutics. Ther Deliv. 2013;4:369–394. doi:10.4155/tde.13.623442082
   PubMedGoogle Scholar
• Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release. 2004;96:273–283. doi:10.1016/j.jconrel.2004.02.00315081218
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta - Gen Subj. 2012;1820:291–317. doi:10.1016/j.bbagen.2011.07.016
   PubMed Web of Science ®Google Scholar
• Wiewrodt R, Thomas AP, Cipelletti L, et al. Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood. 2002;99:912–922. doi:10.1182/blood.V99.3.91211806994
   PubMed Web of Science ®Google Scholar
• Meyer M, Wagner E. pH-responsive shielding of non-viral gene vectors. Expert Opin Drug Deliv. 2006;3:563–571. doi:10.1517/17425247.3.5.56316948553
   PubMedGoogle Scholar
• Hatakeyama H, Akita H, Kogure K, et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 2007;14:68–77. doi:10.1038/sj.gt.330284316915290
   PubMed Web of Science ®Google Scholar
• Geers B, Dewitte H, De Smedt SC, Lentacker I. Crucial factors and emerging concepts in ultrasound-triggered drug delivery. J Control Release. 2012;164:248–255. doi:10.1016/j.jconrel.2012.08.01423320295
   PubMed Web of Science ®Google Scholar
• Wang X, Liu P, Yang W, et al. Microbubbles coupled to methotrexate-loaded liposomes for ultrasound-mediated delivery of methotrexate across the blood-brain barrier. Int J Nanomedicine. 2014;9:4899–4909. doi:10.2147/IJN.S6984525364248
   PubMed Web of Science ®Google Scholar
• Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 2015;219:500–518. doi:10.1016/j.jconrel.2015.07.02426297206
   PubMed Web of Science ®Google Scholar
• Levchenko TS, Hartner WC, Torchilin VP. Liposomes in diagnosis and treatment of cardiovascular disorders. Methodist Debakey Cardiovasc J. 2012;8:36–41. doi:10.14797/mdcj-8-1-3622891109
   PubMedGoogle Scholar
• Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem.Rev. 2015;115:10938–10966. doi:10.1021/acs.chemrev.5b0004626010257
   PubMed Web of Science ®Google Scholar
• Willis L, Hayes D, Mansour HM. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung. 2012;190:251–262. doi:10.1007/s00408-011-9360-x22274758
   PubMed Web of Science ®Google Scholar
• Minko T, Stefanov A, Pozharov V. Selected contribution: lung hypoxia: antioxidant and antiapoptotic effects of liposomal α-tocopherol. J Appl Physiol. 2002;93:1550–1560. doi:10.1152/japplphysiol.00007.200212235059
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Mainelis G, Taratula O, Minko T. Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol Med. 2014;11:44–55. doi:10.7497/j.issn.2095-3941.2014.01.00424738038
   PubMedGoogle Scholar
• Ivanova V, Garbuzenko OB, Reuhl KR, et al. Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur J Pharm Biopharm. 2013;84:335–344. doi:10.1016/j.ejpb.2012.11.02323228437
   PubMed Web of Science ®Google Scholar
• Li N, Weng D, Wang S-M, et al. Surfactant protein-A nanobody-conjugated liposomes loaded with methylprednisolone increase lung-targeting specificity and therapeutic effect for acute lung injury. Drug Deliv. 2017;24:1770–1781. doi:10.1080/10717544.2017.140221729160134
   PubMed Web of Science ®Google Scholar
• Cipolla D, Blanchard J, Gonda I. Development of liposomal ciprofloxacin to treat lung infections. Pharmaceutics. 2016;8:6. doi:10.3390/pharmaceutics8010006
   PubMed Web of Science ®Google Scholar
• Meenach SA, Anderson KW, Hilt JZ, McGarry RC, Mansour HM. High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies. AAPS Pharm Sci Tech. 2014;15:1574–1587. doi:10.1208/s12249-014-0182-z
   PubMed Web of Science ®Google Scholar
• Wang Y, Kho K, Cheow WS, Hadinoto K. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid–polymer hybrid nanoparticles. Int J Pharm. 2012;424:98–106. doi:10.1016/j.ijpharm.2011.12.04522226876
   PubMed Web of Science ®Google Scholar
• Sinha B, Mukherjee B, Pattnaik G. Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: in vitro and in vivo study. Nanomedicine. 2013;9:94–104. doi:10.1016/j.nano.2012.04.00522633899
   PubMed Web of Science ®Google Scholar
• Chen AM, Taratula O, Wei D, et al. Labile catalytic packaging of DNA/siRNA: control of gold nanoparticles “out” of DNA/siRNA complexes. ACS Nano. 2010;4:3679–3688. doi:10.1021/nn901796n20521827
   PubMed Web of Science ®Google Scholar
• Pitard B, Bello-Roufaï M, Lambert O, et al. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Res. 2004;32:e159. doi:10.1093/nar/gnh15315547248
   PubMed Web of Science ®Google Scholar
• Tomoda K, Ohkoshi T, Hirota K, et al. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf B Biointerfaces. 2009;71:177–182. doi:10.1016/j.colsurfb.2009.02.00119264458
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, Romeijn S, Junginger HE, Borchard G. PLGA–PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm Biopharm. 2004;58:1–6. doi:10.1016/j.ejpb.2004.03.00815207531
   PubMed Web of Science ®Google Scholar
• Vij N. Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential. Expert Opin Drug Deliv. 2011;8:1105–1109. doi:10.1517/17425247.2011.59738121711085
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, McLeod VM, Ryan GM, et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J Control Release. 2014;183:18–26. doi:10.1016/j.jconrel.2014.03.01224637466
   PubMed Web of Science ®Google Scholar
• Patil ML, Zhang M, Betigeri S, et al. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem. 2008;19:1396–1403. doi:10.1021/bc800072218576676
   PubMed Web of Science ®Google Scholar
• Khan OF, Zaia EW, Jhunjhunwala S, et al. Dendrimer-inspired nanomaterials for the in vivo delivery of siRNA to lung vasculature. Nano Lett. 2015;15:3008–3016. doi:10.1021/nl504897225789998
   PubMed Web of Science ®Google Scholar
• Bohr A, Tsapis N, Andreana I, et al. Anti-inflammatory effect of anti-TNF-α SiRNA cationic phosphorus dendrimer nanocomplexes administered intranasally in a murine acute lung injury model. Biomacromolecules. 2017;18:2379–2388.28639789
   PubMed Web of Science ®Google Scholar
• Jiang J, Liu Y, Wu C, et al. Development of drug-loaded chitosan hollow nanoparticles for delivery of paclitaxel to human lung cancer A549 cells. Drug Dev Ind Pharm. 2017;43:1304–1313. doi:10.1080/03639045.2017.131889528402175
   PubMed Web of Science ®Google Scholar
• Price DN, Stromberg LR, Kunda NK, Muttil P. In vivo pulmonary delivery and magnetic-targeting of dry powder nano-in-microparticles. Mol Pharm. 2017;14:4741–4750. doi:10.1021/acs.molpharmaceut.7b0053229068693
   PubMed Web of Science ®Google Scholar
• Fytianos K, Chortarea S, Rodriguez-Lorenzo L, et al. Aerosol delivery of functionalized gold nanoparticles target and activate dendritic cells in a 3D lung cellular model. ACS Nano. 2017;11:375–383. doi:10.1021/acsnano.6b0606127973764
   PubMed Web of Science ®Google Scholar
• Bhushan B, Gopinath P. Antioxidant nanozyme: a facile synthesis and evaluation of the reactive oxygen species scavenging potential of nanoceria encapsulated albumin nanoparticles. J Mater Chem. 2015;B3:4843–4852. doi:10.1039/C5TB00572H
   Google Scholar
• Muralidharan P, Hayes D, Black SM, Mansour HM. Microparticulate/nanoparticulate powders of a novel Nrf2 activator and an aerosol performance enhancer for pulmonary delivery targeting the lung Nrf2/Keap-1 pathway. Mol Syst Des Eng. 2016;1:48–65. doi:10.1039/C5ME00004A27774309
   PubMed Web of Science ®Google Scholar
• Roulet A, Armand L, Dagouassat M, et al. Intratracheally administered titanium dioxide or carbon black nanoparticles do not aggravate elastase-induced pulmonary emphysema in rats. BMC Pulm Med. 2012;12:38. doi:10.1186/1471-2466-12-3822849372
   PubMed Web of Science ®Google Scholar
• Al Faraj A, Shaik AS, Afzal S, Al Sayed B, Halwani R. MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int J Nanomedicine. 2014;9:1491–1503. doi:10.2147/IJN.S5939424711699
   PubMed Web of Science ®Google Scholar
• Weng KC, Noble CO, Papahadjopoulos-Sternberg B, et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 2008;8:2851–2857. doi:10.1021/nl801488u18712930
   PubMed Web of Science ®Google Scholar
• Liong M, Lu J, Kovochich M, et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano. 2008;2:889–896. doi:10.1021/nn800072t19206485
   PubMed Web of Science ®Google Scholar
• Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res. 2011;44:1094–1104. doi:10.1021/ar200105p21812415
   PubMed Web of Science ®Google Scholar
• Davis SS. Biomédical applications of nanotechnology — implications for drug targeting and gene therapy. Trends Biotechnol. 1997;15:217–224. doi:10.1016/S0167-7799(97)01036-69183864
   PubMed Web of Science ®Google Scholar
• Sahib MN, Darwis Y, Peh KK, Abdulameer SA, Tan YTF. Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations. Int J Nanomed. 2011;6:2351–2366. doi:10.2147/IJN.S25363
   PubMed Web of Science ®Google Scholar
• Monument MJ, Hart DA, Befus AD, et al. The mast cell stabilizer ketotifen reduces joint capsule fibrosis in a rabbit model of post-traumatic joint contractures. Inflamm Res. 2012;61:285–292. doi:10.1007/s00011-011-0409-322173279
   PubMed Web of Science ®Google Scholar
• Chen DL, Rosenbluth DB, Mintun MA, Schuster DP. FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. J Appl Physiol. 2006;100:1602–1609. doi:10.1152/japplphysiol.01429.200516424067
   PubMed Web of Science ®Google Scholar
• Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–1980.1432158
   PubMed Web of Science ®Google Scholar
• Swaminathan J, Ehrhardt C. Liposomal delivery of proteins and peptides. Expert Opin Drug Deliv. 2012;9:1489–1503. doi:10.1517/17425247.2012.73565823092138
   PubMed Web of Science ®Google Scholar
• Mueller C, Flotte TR. Gene therapy for cystic fibrosis. Clin Rev Allergy Immunol. 2008;35:164–178. doi:10.1007/s12016-008-8080-318600482
   PubMed Web of Science ®Google Scholar
• Al-Jamal R, Wallace W, Harrison D. Gene therapy for chronic obstructive pulmonary disease: twilight or triumph? Expert Opin Biol Ther. 2005;5:333–346. doi:10.1517/14712598.5.3.33315833071
   PubMed Web of Science ®Google Scholar
• Stecenko AA, Brigham KL. Gene therapy progress and prospects: alpha-1 antitrypsin. Gene Ther. 2003;10:95–99. doi:10.1038/sj.gt.330194712571637
   PubMed Web of Science ®Google Scholar
• Metz R, DiCola M, Kurihara T, et al. Mode of action of RNA/DNA oligonucleotides: progress in the development of gene repair as a therapy for alpha(1)-antitrypsin deficiency. Chest. 2002;121:91S–97S. doi:10.1378/chest.121.3_suppl.91S11893721
   PubMed Web of Science ®Google Scholar
• Liu A, Liu L, Chen S, et al. Activation of canonical wnt pathway promotes differentiation of mouse bone marrow-derived MSCs into type II alveolar epithelial cells, confers resistance to oxidative stress, and promotes their migration to injured lung tissue in vitro. J Cell Physiol. 2013;228:1270–1283. doi:10.1002/jcp.2428223154940
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu A, Xu Q, et al. Bone marrow mesenchymal stem cell transplantation for treatment of emphysemic rats. Int J Clin Exp Med. 2014;7:968–972.24955169
   PubMed Web of Science ®Google Scholar
• Rojas M, Xu J, Woods CR, et al. Bone marrow–derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol. 2005;33:145–152. doi:10.1165/rcmb.2004-0330OC15891110
   PubMed Web of Science ®Google Scholar